Emergent Biosolutions' (EBS) shares were up 12% in Wednesday's premarket session after saying it received approximately $400 million in orders for its smallpox and mpox vaccine products.
The biotech firm said it will deliver the treatments, which include its ACAM2000 smallpox vaccine, for the remainder of 2024 and 2025.
Price: 6.84, Change: +0.73, Percent Change: +11.95
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.